ENTITY
INS018_055
INS018_055
PulseAugur coverage of INS018_055 — every cluster mentioning INS018_055 across labs, papers, and developer communities, ranked by signal.
Total · 30d
2
2 over 90d
Releases · 30d
0
0 over 90d
Papers · 30d
1
1 over 90d
TIER MIX · 90D
TOPICS
TIMELINE
- 2026-09-07 research_milestone An AI-designed drug, INS018_055, showed potential in reversing biological aging markers during a phase I clinical trial. source
RECENT · PAGE 1/1 · 2 TOTAL
-
AI-designed drug reverses biological aging markers in early trial
Insilico Medicine's AI-designed drug, INS018_055, has shown promising results in a phase I clinical trial for idiopathic pulmonary fibrosis. The drug, rentosertib, appears to reverse biological aging markers, with six i…
-
Takeda partners with Insilico Medicine for $600M AI drug discovery deal
Takeda Pharmaceutical Company has entered into a strategic collaboration with Insilico Medicine, utilizing AI for early-stage drug discovery. The deal, potentially worth up to US$600 million, grants Takeda exclusive wor…